Lymphoma / 2013 / Article / Fig 3

Research Article

Polo-Like Kinase 1: A Novel Target for the Treatment of Therapy-Resistant Mantle Cell Lymphoma

Figure 3

Viability, proliferation, and apoptosis of primary refractory MCL cells following PLK1 downregulation with BI2536. Viability (a) and proliferation (b) were measured at 24, 48, and 72 hours after treatment using MTT and 3[H]-thymidine uptake assays, respectively, while apoptosis (c) was measured at 48 and 72 hours using annexin-V staining. The values represent the means ± SE from triplicate wells of the 96 well plates. These results are representative from two different MCL patient samples. indicates the statistical difference between control primary MCL cells and PLK1 downregulated primary MCL cells.
782903.fig.003a
(a)
782903.fig.003b
(b)
782903.fig.003c
(c)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.